ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
These 3 Stocks Have Huge Insider Buying30 Aug 2014, 2:36 amAs earnings season comes to an end, so does the opportunity for a company’s officers and directors to snap up company shares with their own money. Most corporate governance policies restrict such
GNC, Southern Copper And Others Insiders Have Been Buying25 Aug 2014, 11:34 amAnnaly Capital Management, GNC Holdings and Southern Copper are among the companies that have seen insider buying recently. Insiders may sell shares for any number of reasons, but conventional wisdom says ...
ARIAD Falls on Wider-than-Expected Loss, Revenues Miss - Analyst Blog11 Aug 2014, 11:26 amARIAD Falls on Wider-than-Expected Loss, Revenues Miss - Analyst Blog
ARIAD Falls on Wider-than-Expected Loss, Revenues Miss11 Aug 2014, 10:10 amARIAD (ARIA) reported a loss of 30 cents per share in the second quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 27 cents.
Why Ariad Pharmaceuticals (ARIA) Stock Is Down Today6 Aug 2014, 11:07 amAriad Pharmaceuticals (ARIA) shares are down after the company reported second quarter earnings and revenue that failed to meet analysts expectations.
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog5 Aug 2014, 3:40 pmWill GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape5 Aug 2014, 7:56 amShould You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings?5 Aug 2014, 4:41 amAriad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings ...
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma1 Aug 2014, 7:14 amLONDON, August 1, 2014 /PRNewswire/ -- On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the...
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics1 Aug 2014, 6:43 amThe Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics